PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27159637-0 2016 Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa. evodiamine 55-65 transient receptor potential cation channel subfamily V member 1 Homo sapiens 37-42 27159637-8 2016 Evodiamine (1), but not rutaecarpine (2), can desensitize or competitively inhibit the activity of TRPV1. evodiamine 0-10 transient receptor potential cation channel subfamily V member 1 Homo sapiens 99-104 26188960-8 2016 Evodiamine induced significant inward currents in TRPV1-, but not TRPA1-transfected HEK293 cells. evodiamine 0-10 transient receptor potential cation channel subfamily V member 1 Homo sapiens 50-55 22942745-0 2012 Binding mode pediction of evodiamine within vanilloid receptor TRPV1. evodiamine 26-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 63-68 26354012-0 2015 [Effects of evodiamine, a major alkaloid of Goshuyu (Evodia Fruits), on TRPV1]. evodiamine 12-22 transient receptor potential cation channel subfamily V member 1 Homo sapiens 72-77 23902373-0 2014 Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels. evodiamine 68-78 transient receptor potential cation channel subfamily V member 1 Homo sapiens 100-105 23902373-1 2014 BACKGROUND AND PURPOSE: Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo. evodiamine 24-34 transient receptor potential cation channel subfamily V member 1 Homo sapiens 186-231 23902373-1 2014 BACKGROUND AND PURPOSE: Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo. evodiamine 24-34 transient receptor potential cation channel subfamily V member 1 Homo sapiens 233-238 23902373-2 2014 Evodiamine is structurally different from all known TRPV1 activators, and has significant clinical potential as a thermogenic agent. evodiamine 0-10 transient receptor potential cation channel subfamily V member 1 Homo sapiens 52-57 23902373-8 2014 CONCLUSIONS AND IMPLICATIONS: Evodiamine qualifies as structurally unique lead structure to develop new potent TRPV1 agonists/desensitizers. evodiamine 30-40 transient receptor potential cation channel subfamily V member 1 Homo sapiens 111-116 24773265-3 2014 These reviews are complemented by original research reports focusing, among others, on the emerging roles of TRPV1 in osteoporosis and cystitis and on evodiamine as a lead structure for the development of potent TRPV1 agonists/desensitizers. evodiamine 151-161 transient receptor potential cation channel subfamily V member 1 Homo sapiens 212-217 22942745-2 2012 It has been reported that evodiamine acts as an agonist of the vanilloid receptor Transient receptor potential vanilloid-1 (TRPV1). evodiamine 26-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 82-122 22942745-2 2012 It has been reported that evodiamine acts as an agonist of the vanilloid receptor Transient receptor potential vanilloid-1 (TRPV1). evodiamine 26-36 transient receptor potential cation channel subfamily V member 1 Homo sapiens 124-129 22942745-3 2012 However, the precise interaction between evodiamine and TRPV1 was still not fully understood. evodiamine 41-51 transient receptor potential cation channel subfamily V member 1 Homo sapiens 56-61 22942745-5 2012 We then performed docking and molecular dynamics simulation to gain a better understanding of the probable binding modes of evodiamine within the TRPV1 binding pocket. evodiamine 124-134 transient receptor potential cation channel subfamily V member 1 Homo sapiens 146-151 22942745-8 2012 This study is the first to shed light on the structural determinants required for the interaction between TRPV1 and evodiamine, and gives new suggestions for the rational design of novel TRPV1 ligands. evodiamine 116-126 transient receptor potential cation channel subfamily V member 1 Homo sapiens 106-111 22942745-8 2012 This study is the first to shed light on the structural determinants required for the interaction between TRPV1 and evodiamine, and gives new suggestions for the rational design of novel TRPV1 ligands. evodiamine 116-126 transient receptor potential cation channel subfamily V member 1 Homo sapiens 187-192 34808100-0 2022 Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway. evodiamine 0-10 transient receptor potential cation channel subfamily V member 1 Homo sapiens 80-85 34808100-2 2022 Our study aims to explain the underlying role of TRPV1/Ca2+ in EVO-induced cytotoxicity in human gastric cancer cells. evodiamine 63-66 transient receptor potential cation channel subfamily V member 1 Homo sapiens 49-54 34808100-17 2022 Pharmacological and genetic inhibition of TRPV1 could significantly attenuate Ca2+ influx, ROS generation and apoptotic cell death induced by EVO exposure, while exogenous TRPV1 overexpression could augment the EVO-induced cytotoxicity. evodiamine 142-145 transient receptor potential cation channel subfamily V member 1 Homo sapiens 42-47 34808100-17 2022 Pharmacological and genetic inhibition of TRPV1 could significantly attenuate Ca2+ influx, ROS generation and apoptotic cell death induced by EVO exposure, while exogenous TRPV1 overexpression could augment the EVO-induced cytotoxicity. evodiamine 211-214 transient receptor potential cation channel subfamily V member 1 Homo sapiens 172-177 34808100-20 2022 Our results support the concept that EVO induces ROS-dependent cytotoxicity via TRPV1/Ca2+ Pathway. evodiamine 37-40 transient receptor potential cation channel subfamily V member 1 Homo sapiens 80-85